Amazon Web Services launched Amazon Bio Discovery, an agentic AI platform designed to speed antibody design with direct access to foundation models and integrated lab partner workflows. The system pairs AI-driven molecule generation and evaluation with an experimentation loop routed through wet-lab partners such as Twist and Ginkgo, with results fed back to refine candidate selection. AWS said it includes an antibody benchmark dataset to estimate properties such as manufacturability and stability, and that early adopters include Bayer, the Broad Institute, Fred Hutch Cancer Center, and Voyager Therapeutics.